Cullinan Oncology Inc reports results for the quarter ended in March - Earnings Summary

Cullinan Therapeutics

15/05/2023 14:32

* Cullinan Oncology Inc  CGEM.OQ  reported a quarterly
adjusted
loss of $1.42​​ per share for the quarter ended in March. The
mean expectation of four analysts for the quarter was for a loss
of 98 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Cullinan Oncology Inc's reported EPS for the quarter was a
loss
of $1.42​.
    * The mean earnings estimate of analysts had fallen by
about 33%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Cullinan Oncology Inc shares had fallen by 4.6% this
quarter and
lost 7.5% so far this year.
    * The company reported a quarterly loss of $57.96 million.
    * Wall Street's median 12-month price target for Cullinan
Oncology
Inc is $23.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
15 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.98          -1.42          Missed
 Dec. 31 2022      -0.66          -0.59          Beat
 Sep. 30 2022      -0.97          -0.54          Beat
 Jun. 30 2022      5.42           3.77           Missed